These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38783407)

  • 1. Transparency, reproducibility, and replicability of pharmacoepidemiology studies in a distributed network environment.
    Rai A; Maro JC; Dutcher S; Bright P; Toh S
    Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5820. PubMed ID: 38783407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
    Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
    Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The US Food and Drug Administration Sentinel System: a national resource for a learning health system.
    Brown JS; Mendelsohn AB; Nam YH; Maro JC; Cocoros NM; Rodriguez-Watson C; Lockhart CM; Platt R; Ball R; Dal Pan GJ; Toh S
    J Am Med Inform Assoc; 2022 Nov; 29(12):2191-2200. PubMed ID: 36094070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.
    Dhodapkar MM; Shi X; Ramachandran R; Chen EM; Wallach JD; Ross JS
    BMJ; 2022 Oct; 379():e071752. PubMed ID: 36198428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database.
    Sonawane KB; Cheng N; Hansen RA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):682-690. PubMed ID: 29952714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration's Sentinel system.
    Brown JS; Maro JC; Nguyen M; Ball R
    J Am Med Inform Assoc; 2020 May; 27(5):793-797. PubMed ID: 32279080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
    Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias.
    Platt RW; Platt R; Brown JS; Henry DA; Klungel OH; Suissa S
    Pharmacoepidemiol Drug Saf; 2019 Jan; ():. PubMed ID: 30648307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the U.S. Food and Drug Administration's Sentinel Routine Querying Tools to the Taiwan Sentinel Data Model-formatted National Health Insurance Research Database.
    Lin FJ; Huang LY; Wang CC; Toh S
    J Food Drug Anal; 2023 Dec; 31(4):772-781. PubMed ID: 38526825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
    Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
    Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed?
    Alla F; Rosilio M; Funck-Brentano C; ; Barthélémy P; Brisset S; Cellier D; Chassany O; Demarez JP; Diebolt V; Francillon A; Gambotti L; Hannachi H; Lechat P; Lemaire F; Lièvre M; Misse C; Nguon M; Pariente A; Rosenheim M; Weisslinger-Darmon N
    Therapie; 2013; 68(4):209-23. PubMed ID: 23981258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants.
    Wong CK; Ho SS; Saini B; Hibbs DE; Fois RA
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):731-7. PubMed ID: 26017154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.